CNIPA’s 2026 administrative protection work plan calls for closer coordination with commerce authorities and stricter management of outbound intellectual property transfers connected to technology exports. The measure does not create a wholly new approval track, but it points to more disciplined review of cross-border deals involving restricted technologies, core patents, software rights and other strategic know-how.
For companies in biopharmaceuticals and advanced manufacturing, the practical risk extends beyond an outright patent sale. Exclusive licences, bundled technology packages and control changes may also attract scrutiny. Businesses should classify the technology, verify ownership and licensing scope, and build a clear record of the deal’s purpose and likely impact before signing. Tighter review is not the same as a blanket ban, but transactions that leave compliance until after execution may face greater delay and closing uncertainty.
